A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer
- PMID: 26048455
- DOI: 10.1016/j.ejca.2015.04.028
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer
Abstract
Background: Bicalutamide blocks androgen action and is frequently used in men with non-metastatic, castration-resistant prostate cancer (CRPC). By reducing intracellular dihydrotestosterone, dutasteride (dual 5-alpha reductase inhibitor) could increase the effectiveness of bicalutamide in this setting. The objective of the study is therefore to prospectively evaluate dutasteride plus bicalutamide in men with asymptomatic, non-metastatic CRPC with rising prostate-specific antigen (PSA).
Methods: Prostate cancer patients with rising PSA whilst on first-line androgen deprivation therapy (ADT) were randomised (1:1) in a double-blind trial to receive bicalutamide 50mg plus placebo or bicalutamide 50mg plus dutasteride 3.5mg once daily for 18 months. Randomisation was stratified by centre; treatment assignments were generated using GlaxoSmithKline's RandAll System. Subjects who completed 18 months could participate in the 2-year extension. Central laboratory and study sites/monitors remained treatment-blinded. Primary end-point was time to disease progression (TDP) up to 42 months (defined as PSA progression from baseline or nadir, radiographic disease progression, death from prostate cancer or receipt of rescue medication).
Findings: There was no statistically significant difference in TDP in 127 men treated with bicalutamide/dutasteride (n=62) compared with bicalutamide/placebo (n=65) (hazard ratio (HR)=0.94 [95% confidence interval (CI) 0.61, 1.46]; p=0.79). The estimated median TDP was 425 days (95% CI 302, 858) in the bicalutamide/placebo group and 623 days (95% CI 369, 730) in the bicalutamide/dutasteride group. There was no statistically significant difference between the treatment groups for any secondary efficacy end-points, including time to treatment failure or PSA response. In the multivariate analysis, age, non-White race, higher baseline testosterone and lower baseline PSA were associated with longer TDP. Adverse events were comparable between treatment groups.
Interpretation: In men with non-metastatic CRPC, adding dutasteride to bicalutamide did not significantly prolong TDP. Prospective data are provided concerning the common practice of using bicalutamide in this setting.
Keywords: Androgen deprivation therapy (ADT); Bicalutamide; Castration-resistant prostate cancer (CRPC); Dutasteride; Prostate-specific antigen (PSA).
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.Can J Urol. 2009 Oct;16(5):4806-12. Can J Urol. 2009. PMID: 19796455 Clinical Trial.
-
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348
-
Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.Eur J Cancer. 2015 Jul;51(10):1283-92. doi: 10.1016/j.ejca.2015.03.021. Epub 2015 Apr 16. Eur J Cancer. 2015. PMID: 25892647 Clinical Trial.
-
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.Cochrane Database Syst Rev. 2014 Jun 30;2014(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Cochrane Database Syst Rev. 2014. PMID: 24979481 Free PMC article. Review.
-
Bicalutamide dosages used in the treatment of prostate cancer.Prostate. 1999 Apr 1;39(1):47-53. doi: 10.1002/(sici)1097-0045(19990401)39:1<47::aid-pros8>3.0.co;2-x. Prostate. 1999. PMID: 10221266 Review.
Cited by
-
Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.Onco Targets Ther. 2020 Sep 18;13:9257-9267. doi: 10.2147/OTT.S245861. eCollection 2020. Onco Targets Ther. 2020. PMID: 32982312 Free PMC article.
-
Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis.PeerJ. 2020 Jun 1;8:e9282. doi: 10.7717/peerj.9282. eCollection 2020. PeerJ. 2020. PMID: 32547884 Free PMC article.
-
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.Int J Biol Sci. 2016 Feb 6;12(4):409-26. doi: 10.7150/ijbs.14090. eCollection 2016. Int J Biol Sci. 2016. PMID: 27019626 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous